reading oral GLP-1 threads from 2024 and half of it aged badly
Posting this as a discussion rather than a claim: reading oral GLP-1 threads from 2024 and half of it aged badly. What is actually known, and what is being assumed. Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its…
I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.
Correcting myself: that was a phase 2 readout and I described it as phase 3.
ATTAIN and ACHIEVE are the programmes to keep straight
the manufacturing story is genuinely different from the injectables
oral semaglutide is a peptide with an absorption enhancer, this is not that
small molecule, not a peptide, and that changes everything about it
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
no food and water restrictions is the practical difference people care about
Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.